Cytokine changes during interferon-beta therapy in multiple sclerosis: Correlations with interferon dose and MRI response
Cytokine changes during interferon-beta therapy in multiple sclerosis: Correlations with interferon dose and MRI response
复制标题
DOI：
10.1016/j.jneuroim.2007.01.011
复制
发表时间：
2007-04-01
影响因子：
3.3
通讯作者：
Dhib-Jalbut, Suhayl
中科院分区：
文献类型：
--
作者：
Graber, Jerome J.;Ford, David;Dhib-Jalbut, Suhayl
我们研究了血清（IL-10和IL-12 p70）和细胞因子水平（IL-10，IL-12p40，IL-12p70，15名复发缓解型多发性硬化症（MS）患者随机接受每周一次（qw）IFN-β-1a 30 μ g肌内（IM）（n=8）或每周三次（tiw）IFN-β-1a 30 μ g肌内（IM）（n=8），1a 44 μ g皮下（SC）（n=7）。总的来说，IFN-β治疗增加了细胞IL-10（p < 0.01）水平和细胞IL-10/IL-12 p40（p < 0.01）和IL-10/IL-12 p70（p < 0.02）的比率，而细胞IFN-γ水平降低（p < 0.01）。根据MRI定义的标准，治疗无效者血清IL-10水平降低（p
We investigated serum (IL-10 and IL-12p70) and cellular cytokine levels (IL-10, IL-12p40, IL-12p70, IFN-gamma) in stimulated PBMC over 24 weeks in 15 relapsing-remitting multiple sclerosis (MS) patients randomized to receive once-weekly (qw) IFN-beta-1a 30 mu g intramuscularly (IM) (n=8) or three-times-weekly (tiw) IFN-beta-1a 44 mu g subcutaneously (SC) (n=7). Overall, IFN-beta treatment increased cellular IL-10 (p < 0.01) levels and the ratios of cellular IL-10/IL-12p40 (p < 0.01) and IL-10/IL-12p70 (p < 0.02) while cellular IFN-gamma levels were reduced (p < 0.01). Serum IL-10 levels were decreased in non-responders to therapy based on MRI-defined criteria (p